Merck (MRK) announced that KEYTRUDA, in combination with Padcev, is approved in the EU as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for adults with resectable MIBC
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES